Leukemia

The CHMP recommended pirtobrutinib in chronic lymphocytic leukemia based on data from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials.

Those with TP53-mutated disease may benefit from continuous BTK inhibitor therapy, although limited-duration therapy is worthy of discussion.

Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

In BRUIN CLL-322, fixed-duration pirtobrutinib plus venetoclax/rituximab improved PFS vs venetoclax/rituximab in relapsed/refractory CLL.

Combining pirtobrutinib with venetoclax/rituximab yielded high MRD clearance among those with CLL/SLL in the phase 3 BRUIN CLL-322 trial.

In KOMET-007, ziftomenib plus 7+3 produced high responses and MRD-negativity rates in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.

MRD responses appeared to be more favorable with the use of blinatumomab among pediatric patients with high-risk B-cell acute lymphoblastic leukemia.

A phase 1b/2 trial of azacitidine, venetoclax, and ivosidenib showed composite complete remissions and MRD negativity in newly diagnosed IDH1-mutated AML.

Findings from the ASC4FIRST trial show that asciminib is meeting high expectations as a frontline therapy in chronic myeloid leukemia in chronic phase.

Data from the CASSIOPEIA trial showed that more than half of patients with high-risk disease achieved 5-year disease-free survival with tisagenlecleucel.

Updated data from the ASC4FIRST trial affirm asciminib as the treatment of choice for many patients with chronic myeloid leukemia in chronic phase.

The safe administration of revumenib among pediatric patients broadens the applicability of results seen with the menin inhibitor.

Real-world data support prospective evaluation of a frontline venetoclax-based regimen in the second line and beyond.

More than 90% of patients achieved a composite complete response to azacitidine plus venetoclax and ivosidenib in a phase 1b/2 trial.

The nilotinib tablets may support patients who have difficulty swallowing while offering flexibility to take treatment with or without water.

Fedratinib may target various proliferative pathways in MDS/MPN that other current standards of care miss, according to Andrew Kuykendall, MD.

Researchers have shown that mycophenolate mofetil accelerates neutrophil engraftment compared to methotrexate in cord blood transplantation.

Data from a phase 2 trial show that quizartinib plus omacetaxine mepesuccinate may better position patients to proceed to consolidative transplantation.

Investigators are assessing CLN-049 among patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome in a phase 1 study.

Data from the phase 1/2 ASTX727-07 study support the FDA approval of decitabine plus cedazuridine and venetoclax in this AML population.

The ASPHO Conference brings together the world’s leading experts in pediatric oncology and hematology, and this collection of posters detail new findings in care.

Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.

New developments revealed regulatory milestones for bacterial therapeutic candidates and potential efficacy with vaccine-based approaches.

Hematologic oncologists discussed long-term survival data from the SEQUOIA and ALPINE trials exploring zanubrutinib in frontline and R/R CLL/SLL.